Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer
Kei Kudo(National Institutes of Health), Christina M. Annunziata(National Cancer Institute)
Cited by 3
Related Papers
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
Activation of NF-κB Signaling by Inhibitor of NF-κB Kinase β Increases Aggressiveness of Ovarian Cancer
|Cancer Research|2010|115
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells
|Proceedings of the National Academy of Sciences|2012|72
IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts
|BMC Cancer|2018|27
Disulfiram Transcends ALDH Inhibitory Activity When Targeting Ovarian Cancer Tumor-Initiating Cells
|Frontiers in Oncology|2022|24